VerImmune is an Immuno-Oncology company developing a first-in-class cancer therapy known as Anti-tumor Immune Redirection.
VerImmune has raised $4.5M in total funding. The most recent round was Seed. The last funding was announced in September 2024.
VerImmune's investors include National Science Foundation, Gaingels, Ulu Ventures, Mana Ventures, Fosun Pharma.
VerImmune is headquartered in Baltimore, United States.
VerImmune is an Immuno-Oncology company developing a first-in-class cancer therapy known as Anti-tumor Immune Redirection.
VerImmune is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"VerImmune — Funding & Investors." VCBacked, September 23, 2024, https://www.vcbacked.co/company/verimmune. Accessed July 19, 2026.
VCBacked. (2024). VerImmune — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/verimmune
{{cite web |title=VerImmune — Funding & Investors |url=https://www.vcbacked.co/company/verimmune |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated